commercial-leadership
(5)
Jeremy Shepherd Has Spent Two Decades Learning Where a Brand Meets the Buyer
Before Jeremy Shepherd became Brown-Forman's chief marketing officer, he spent two decades close to the places where strategy gets tested - markets, distributors, stores and teams. His route from Canada to London to Louisville explains the operator behind the title.
David Carey
David Carey is the Chief Executive Officer of Preceptis Medical, the Golden Valley, Minnesota company behind the Hummingbird Tympanostomy Tube System, an FDA-cleared device that lets clinicians place pediatric ear tubes in the office without general anesthesia. Appointed CEO in July 2025, Carey brings three decades of commercial leadership across the medical device industry, including senior roles at Pristine Surgical, Stryker, Medtronic, and Invuity, where he helped guide the company through an IPO before its acquisition by Stryker. At Preceptis, he is focused on scaling the Hummingbird device to more surgeons and families nationwide.
Philina Lee
Philina Lee, PhD is the Chief Executive Officer of AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer built on a proprietary Lead-212 platform. A biopharmaceutical executive with more than two decades in oncology, she was Chief Commercial Officer at Blueprint Medicines (acquired by Sanofi for roughly $9.5 billion) and earlier helped build the organization at Algeta that launched Xofigo, the first approved alpha therapy. Trained as a cell biologist at MIT, she took the AdvanCell helm on January 1, 2026 to lead the company's US expansion from a new Boston-area headquarters and advance its lead candidate 212Pb-ADVC001 for prostate cancer.
Heidi Gillmore
Heidi Gillmore is a commercial leadership executive at TerSera Therapeutics, the Deerfield, Illinois specialty pharmaceutical company she helped build from its 2016 inception. Across roles spanning marketing, strategy, business development and running TerSera's US oncology business, she has helped turn a portfolio of 'one-and-only' therapeutics, including the prostate and breast cancer drug Zoladex, into a durable commercial enterprise. A University of Northern Iowa graduate with a University of Chicago credential, she sits on the board of the Illinois Biotechnology Innovation Organization and has spent her career taking specialty and orphan medicines from acquisition to market.
Shawn O'Neil
Shawn O'Neil is the CEO of ViaLase, a clinical-stage medtech company building FLIGHT, an incision-free femtosecond laser procedure for glaucoma. He spent more than two decades at Alcon rising to head of sales and marketing for surgical glaucoma, then ran commercial at Sight Sciences before joining ViaLase as Chief Commercial Officer and stepping up to CEO in July 2025. His career has been a running tour of the products that reshaped eye surgery: EX-PRESS, LenSx, CyPass, OMNI, TearCare, and now a laser that treats glaucoma without ever touching the eye with a blade.